HRP960272B1 - Heterocyclic compounds - Google Patents
Heterocyclic compoundsInfo
- Publication number
- HRP960272B1 HRP960272B1 HR960272A HRP960272A HRP960272B1 HR P960272 B1 HRP960272 B1 HR P960272B1 HR 960272 A HR960272 A HR 960272A HR P960272 A HRP960272 A HR P960272A HR P960272 B1 HRP960272 B1 HR P960272B1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- alkoxy
- alkylcarbamoyl
- alkoxycarbonyl
- carboxy
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 33
- -1 (2-6C) -alkynyl Chemical group 0.000 abstract 17
- 125000003545 alkoxy group Chemical group 0.000 abstract 17
- 125000005115 alkyl carbamoyl group Chemical group 0.000 abstract 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 7
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 6
- 125000004414 alkyl thio group Chemical group 0.000 abstract 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 3
- 229910003827 NRaRb Inorganic materials 0.000 abstract 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000003302 alkenyloxy group Chemical group 0.000 abstract 2
- 125000005153 alkyl sulfamoyl group Chemical group 0.000 abstract 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 abstract 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 239000001301 oxygen Chemical group 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 229910052717 sulfur Chemical group 0.000 abstract 2
- 239000011593 sulfur Chemical group 0.000 abstract 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000005236 alkanoylamino group Chemical group 0.000 abstract 1
- 125000005092 alkenyloxycarbonyl group Chemical group 0.000 abstract 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 abstract 1
- 125000005281 alkyl ureido group Chemical group 0.000 abstract 1
- 125000005530 alkylenedioxy group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract 1
- 125000001589 carboacyl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 abstract 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000005505 thiomorpholino group Chemical group 0.000 abstract 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 abstract 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9511507.7A GB9511507D0 (en) | 1995-06-07 | 1995-06-07 | Heterocyclic compounds |
| GBGB9519666.3A GB9519666D0 (en) | 1995-09-27 | 1995-09-27 | Heterocyclic derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP960272A2 HRP960272A2 (en) | 1997-08-31 |
| HRP960272B1 true HRP960272B1 (en) | 2006-06-30 |
Family
ID=26307176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR960272A HRP960272B1 (en) | 1995-06-07 | 1996-06-06 | Heterocyclic compounds |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US5866568A (cs) |
| EP (1) | EP0832082B1 (cs) |
| JP (1) | JP3193058B2 (cs) |
| KR (1) | KR100451523B1 (cs) |
| CN (1) | CN1097051C (cs) |
| AR (1) | AR003132A1 (cs) |
| AT (1) | ATE209200T1 (cs) |
| AU (1) | AU715041B2 (cs) |
| BR (1) | BR9608611A (cs) |
| CA (1) | CA2219742C (cs) |
| CZ (1) | CZ289387B6 (cs) |
| DE (1) | DE69617236T2 (cs) |
| DK (1) | DK0832082T3 (cs) |
| EG (1) | EG25227A (cs) |
| ES (1) | ES2168487T3 (cs) |
| GE (1) | GEP20053470B (cs) |
| HR (1) | HRP960272B1 (cs) |
| HU (1) | HUP9802300A3 (cs) |
| IL (1) | IL122464A (cs) |
| MX (1) | MX9709521A (cs) |
| MY (1) | MY114926A (cs) |
| NO (1) | NO314503B1 (cs) |
| NZ (1) | NZ308619A (cs) |
| PL (1) | PL187897B1 (cs) |
| PT (1) | PT832082E (cs) |
| RU (1) | RU2172738C2 (cs) |
| SK (1) | SK282338B6 (cs) |
| TR (1) | TR199701502T1 (cs) |
| TW (1) | TW340845B (cs) |
| UA (1) | UA58494C2 (cs) |
| WO (1) | WO1996040681A1 (cs) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5962490A (en) | 1987-09-25 | 1999-10-05 | Texas Biotechnology Corporation | Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| US6342610B2 (en) | 1993-05-20 | 2002-01-29 | Texas Biotechnology Corp. | N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| US6541498B2 (en) | 1993-05-20 | 2003-04-01 | Texas Biotechnology | Benzenesulfonamides and the use thereof to modulate the activity of endothelin |
| US6613804B2 (en) | 1993-05-20 | 2003-09-02 | Encysive Pharmaceuticals, Inc. | Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin |
| US6376523B1 (en) | 1994-05-20 | 2002-04-23 | Texas Biotechnology Corporation | Benzenesulfonamides and the use thereof to modulate the activity of endothelin |
| US5612359A (en) * | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| US5760038A (en) * | 1995-02-06 | 1998-06-02 | Bristol-Myers Squibb Company | Substituted biphenyl sulfonamide endothelin antagonists |
| US5780473A (en) * | 1995-02-06 | 1998-07-14 | Bristol-Myers Squibb Company | Substituted biphenyl sulfonamide endothelin antagonists |
| US5846990A (en) * | 1995-07-24 | 1998-12-08 | Bristol-Myers Squibb Co. | Substituted biphenyl isoxazole sulfonamides |
| JPH09124620A (ja) | 1995-10-11 | 1997-05-13 | Bristol Myers Squibb Co | 置換ビフェニルスルホンアミドエンドセリン拮抗剤 |
| US5977117A (en) | 1996-01-05 | 1999-11-02 | Texas Biotechnology Corporation | Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin |
| US5856507A (en) * | 1997-01-21 | 1999-01-05 | Bristol-Myers Squibb Co. | Methods for the preparation of biphenyl isoxazole sulfonamides |
| WO1997029747A1 (en) | 1996-02-20 | 1997-08-21 | Bristol-Myers Squibb Company | Methods for the preparation of biphenyl isoxazole sulfonamides |
| US5939446A (en) * | 1996-04-09 | 1999-08-17 | Bristol-Myers Squibb Co. | Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists |
| US5804585A (en) | 1996-04-15 | 1998-09-08 | Texas Biotechnology Corporation | Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin |
| GB9614804D0 (en) * | 1996-07-15 | 1996-09-04 | Chiroscience Ltd | Resolution process |
| TW536540B (en) * | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| AU6187898A (en) * | 1997-01-30 | 1998-08-25 | Bristol-Myers Squibb Company | Method for preventing or treating low renin hypertension by administering an endothelin antagonist |
| GB9704762D0 (en) | 1997-03-07 | 1997-04-23 | Zeneca Ltd | Chemical process |
| SG100767A1 (en) | 1997-04-28 | 2003-12-26 | Texas Biotechnology Corp | Sulfonamides for treatment of endothelin-mediated disorders |
| US5783705A (en) | 1997-04-28 | 1998-07-21 | Texas Biotechnology Corporation | Process of preparing alkali metal salys of hydrophobic sulfonamides |
| IL144708A0 (en) | 1999-03-19 | 2002-06-30 | Bristol Myers Squibb Co | Methods for the preparation of biphenyl isoxazole sulfonamide derivatives |
| US6448239B1 (en) * | 1999-06-03 | 2002-09-10 | Trustees Of Princeton University | Peroxynitrite decomposition catalysts and methods of use thereof |
| JP4202649B2 (ja) | 1999-12-31 | 2008-12-24 | エンサイシブ・ファーマシューティカルズ・インコーポレイテッド | エンドセリンの活性を調節するスルホンアミドおよびそれらの誘導体 |
| US6639082B2 (en) | 2000-10-17 | 2003-10-28 | Bristol-Myers Squibb Company | Methods for the preparation of biphenyl isoxazole sulfonamides |
| US7041280B2 (en) * | 2001-06-29 | 2006-05-09 | Genzyme Corporation | Aryl boronate functionalized polymers for treating obesity |
| US6858592B2 (en) | 2001-06-29 | 2005-02-22 | Genzyme Corporation | Aryl boronic acids for treating obesity |
| GB0219660D0 (en) | 2002-08-23 | 2002-10-02 | Astrazeneca Ab | Therapeutic use |
| GB0223854D0 (en) * | 2002-10-12 | 2002-11-20 | Astrazeneca Ab | Therapeutic treatment |
| RU2234331C1 (ru) * | 2002-12-30 | 2004-08-20 | Смирнов Алексей Владимирович | Лекарственное средство |
| US7169805B2 (en) * | 2003-05-28 | 2007-01-30 | Nicox S.A. | Captopril derivatives |
| GB0320806D0 (en) * | 2003-09-05 | 2003-10-08 | Astrazeneca Ab | Therapeutic treatment |
| GB0403744D0 (en) * | 2004-02-20 | 2004-03-24 | Astrazeneca Ab | Chemical process |
| KR100839512B1 (ko) * | 2004-07-02 | 2008-06-19 | 주식회사 코오롱 | 설파제를 디아조화체로 하는 산성 항균 염료 및 그를이용한 항균 섬유 |
| PT1791811E (pt) * | 2004-09-21 | 2010-02-23 | Astellas Pharma Inc | ¿derivados de aminoálcool |
| US20090209492A1 (en) | 2004-11-12 | 2009-08-20 | Trustees Of Tufts College | Lipase Inhibitors |
| US20070054325A1 (en) * | 2005-04-14 | 2007-03-08 | Reglia | Materials and methods for screening modulators of neural regeneration |
| GB0514743D0 (en) * | 2005-07-19 | 2005-08-24 | Astrazeneca Ab | Salt |
| RU2492185C2 (ru) | 2005-12-13 | 2013-09-10 | Астразенека Аб | Связывающие протеины, специфичные по отношению к инсулин-подобным факторам роста, и их использование |
| CN101437818A (zh) * | 2006-03-03 | 2009-05-20 | 托伦特药物有限公司 | At1和eta受体的新的双重作用受体拮抗剂(dara) |
| RU2435585C2 (ru) * | 2006-04-13 | 2011-12-10 | Актелион Фармасьютиклз Лтд | Антагонисты рецептора эндотелина, предназначенные для ранней стадии идиопатического фиброза легких |
| BRPI0717106A2 (pt) * | 2006-09-21 | 2013-10-08 | Piramal Life Sciences Ltd | Compostos para o tratamento de distúrbios metabólicos |
| CL2008000191A1 (es) | 2007-01-25 | 2008-08-22 | Astrazeneca Ab | Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer. |
| SG174809A1 (en) | 2007-05-03 | 2011-10-28 | Intermune Inc | Macrocyclic compounds useful as inhibitors of hepatitis c virus |
| HRP20120085T1 (hr) * | 2007-10-12 | 2012-02-29 | Astrazeneca Ab | Pripravak zibotentana koji sadrži manitol i mikrokristalnu celulozu |
| NZ600238A (en) | 2008-06-19 | 2014-04-30 | Takeda Pharmaceutical | Heterocyclic compound and use thereof |
| MY155374A (en) * | 2009-02-06 | 2015-10-15 | Nippon Shinyaku Co Ltd | Aminopyrazine derivative and medicine |
| CN102491973A (zh) * | 2011-12-15 | 2012-06-13 | 南京友杰医药科技有限公司 | Zd-4054的合成方法 |
| WO2020165226A1 (en) | 2019-02-12 | 2020-08-20 | The University Court Of The University Of Glasgow | Microvascular angina |
| WO2021262998A1 (en) * | 2020-06-25 | 2021-12-30 | Wake Forest University Health Sciences | Compounds for sensing reactive oxygen species and methods for using the same |
| AU2021305983B2 (en) | 2020-07-10 | 2024-05-16 | Astrazeneca Ab | Combination of zibotentan and dapagliflozin for the treatment of chronic kidney disease |
| AU2022297082B2 (en) | 2021-06-22 | 2024-04-18 | Alchemedicine, Inc. | Compound, endothelin A receptor antagonist and pharmaceutical composition |
| WO2024033519A1 (en) | 2022-08-12 | 2024-02-15 | Astrazeneca Ab | Combination therapies for treatment of cirrhosis with portal hypertension |
| TW202446375A (zh) | 2023-02-08 | 2024-12-01 | 瑞典商阿斯特捷利康公司 | 用於治療高蛋白尿慢性腎病的齊泊騰坦和達格列淨之組合 |
| WO2025133907A1 (en) | 2023-12-18 | 2025-06-26 | Astrazeneca Ab | Combination of zibotentan and dapagliflozin for the treatment of microvascular angina |
| WO2025163559A1 (en) | 2024-02-01 | 2025-08-07 | Astrazeneca Ab | Combination of zibotentan and dapagliflozin for use for the treatment of hypertension |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0655708B2 (ja) * | 1985-05-13 | 1994-07-27 | 三井東圧化学株式会社 | スルホンアミド系化合物及び農業用殺菌剤 |
| RU2043718C1 (ru) * | 1986-01-31 | 1995-09-20 | Исихара Сангио Кайся Лтд. | Способ борьбы с нежелательным ростом растений |
| US5514691A (en) * | 1993-05-20 | 1996-05-07 | Immunopharmaceutics, Inc. | N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| US5591761A (en) * | 1993-05-20 | 1997-01-07 | Texas Biotechnology Corporation | Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| US5464853A (en) * | 1993-05-20 | 1995-11-07 | Immunopharmaceutics, Inc. | N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin |
| US5571821A (en) * | 1993-05-20 | 1996-11-05 | Texas Biotechnology Corporation | Sulfonamides and derivatives thereof that modulate the activity of endothelin |
| US5594021A (en) * | 1993-05-20 | 1997-01-14 | Texas Biotechnology Corporation | Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin |
| EP0462179A4 (en) * | 1989-02-27 | 1992-03-18 | The Du Pont Merck Pharmaceutical Company | Novel sulfonamides as radiosensitizers |
| TW270116B (cs) * | 1991-04-25 | 1996-02-11 | Hoffmann La Roche | |
| AU1929292A (en) * | 1991-05-14 | 1992-12-30 | Hybritech Incorporated | Polymeric compositions having bound antibodies |
| RU2086544C1 (ru) * | 1991-06-13 | 1997-08-10 | Хоффманн-Ля Рош АГ | Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина |
| TW224462B (cs) * | 1992-02-24 | 1994-06-01 | Squibb & Sons Inc | |
| WO1993021219A1 (en) * | 1992-04-22 | 1993-10-28 | Warner-Lambert Company | Endothelin antagonists ii |
| NZ247440A (en) * | 1992-05-06 | 1995-04-27 | Squibb & Sons Inc | Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof |
| EP0650484B1 (en) * | 1992-07-17 | 2000-01-26 | Smithkline Beecham Corporation | Endothelin receptor antagonists |
| TW287160B (cs) * | 1992-12-10 | 1996-10-01 | Hoffmann La Roche | |
| EP0626174A3 (en) * | 1993-04-21 | 1996-01-03 | Takeda Chemical Industries Ltd | Method and composition for the prophylaxis and / or treatment of underactive organs. |
| US5965732A (en) * | 1993-08-30 | 1999-10-12 | Bristol-Myers Squibb Co. | Sulfonamide endothelin antagonists |
| GB9504854D0 (en) * | 1994-03-31 | 1995-04-26 | Zeneca Ltd | Nitrogen derivatives |
| GB9409618D0 (en) * | 1994-05-13 | 1994-07-06 | Zeneca Ltd | Pyridine derivatives |
| DE4426346A1 (de) * | 1994-07-25 | 1996-02-01 | Basf Ag | Herbizide Pyrazinderivate |
| US5612359A (en) * | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| GB2295616A (en) * | 1994-12-01 | 1996-06-05 | Zeneca Ltd | N-Diazine-benzenesulphonamide derivatives as endothelin receptor antagonists |
| NZ500282A (en) * | 1995-04-04 | 2000-01-28 | Texas Biotechnology Corp | Use of thienyl, furyl, pyrrolyl and biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin |
-
1996
- 1996-03-06 UA UA98010043A patent/UA58494C2/uk unknown
- 1996-06-03 KR KR1019970708807A patent/KR100451523B1/ko not_active Expired - Fee Related
- 1996-06-03 CZ CZ19973887A patent/CZ289387B6/cs not_active IP Right Cessation
- 1996-06-03 HU HU9802300A patent/HUP9802300A3/hu unknown
- 1996-06-03 DK DK96919941T patent/DK0832082T3/da active
- 1996-06-03 AU AU58403/96A patent/AU715041B2/en not_active Ceased
- 1996-06-03 BR BR9608611A patent/BR9608611A/pt not_active IP Right Cessation
- 1996-06-03 RU RU98100054/04A patent/RU2172738C2/ru not_active IP Right Cessation
- 1996-06-03 WO PCT/GB1996/001295 patent/WO1996040681A1/en active IP Right Grant
- 1996-06-03 ES ES96919941T patent/ES2168487T3/es not_active Expired - Lifetime
- 1996-06-03 EP EP96919941A patent/EP0832082B1/en not_active Expired - Lifetime
- 1996-06-03 PL PL96324660A patent/PL187897B1/pl not_active IP Right Cessation
- 1996-06-03 NZ NZ308619A patent/NZ308619A/xx not_active IP Right Cessation
- 1996-06-03 CN CN96196149A patent/CN1097051C/zh not_active Expired - Fee Related
- 1996-06-03 CA CA002219742A patent/CA2219742C/en not_active Expired - Fee Related
- 1996-06-03 TR TR97/01502T patent/TR199701502T1/xx unknown
- 1996-06-03 AT AT96919941T patent/ATE209200T1/de active
- 1996-06-03 SK SK1680-97A patent/SK282338B6/sk not_active IP Right Cessation
- 1996-06-03 MX MX9709521A patent/MX9709521A/es unknown
- 1996-06-03 DE DE69617236T patent/DE69617236T2/de not_active Expired - Lifetime
- 1996-06-03 JP JP50020997A patent/JP3193058B2/ja not_active Expired - Fee Related
- 1996-06-03 PT PT96919941T patent/PT832082E/pt unknown
- 1996-06-03 IL IL12246496A patent/IL122464A/en not_active IP Right Cessation
- 1996-06-04 TW TW085106632A patent/TW340845B/zh not_active IP Right Cessation
- 1996-06-04 US US08/658,969 patent/US5866568A/en not_active Expired - Lifetime
- 1996-06-04 MY MYPI96002166A patent/MY114926A/en unknown
- 1996-06-04 AR ARP960102899A patent/AR003132A1/es active IP Right Grant
- 1996-06-06 EG EG50996A patent/EG25227A/xx active
- 1996-06-06 HR HR960272A patent/HRP960272B1/xx not_active IP Right Cessation
-
1997
- 1997-12-05 NO NO19975700A patent/NO314503B1/no not_active IP Right Cessation
-
1998
- 1998-12-14 US US09/211,483 patent/US6060475A/en not_active Expired - Lifetime
-
2000
- 2000-02-15 US US09/504,364 patent/US6258817B1/en not_active Expired - Lifetime
-
2004
- 2004-07-19 GE GE5624A patent/GEP20053470B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP960272B1 (en) | Heterocyclic compounds | |
| ES8603470A1 (es) | Procedimiento de obtencion de compuestos de 1-aril-2-(3-(4-trifluormetilestiril)-1,2,4-triazol-1-il)-1-c 1,2,4,-triazol-1-il-metil) etanol de efecto antifugal. | |
| HUT74093A (en) | Oxazolidinone derivatives as adhesion-receptor antagonists, pharmaceutical compositions containing them and process for their preparation | |
| NO943495D0 (no) | Kondenserte sykliske forbindelser og deres anvendelse | |
| ES8202334A1 (es) | Un procedimiento para la preparacion de derivados de 2,4-diaminoquinazolina | |
| ES8206523A1 (es) | Procedimiento para la obtencion de acidos 7-amino-1-ciclo- propil-4-oxo-1,4-dihidro-naftirin-3-carboxilicos | |
| IL100899A (en) | Beta-amino-alpha- hydroxycarboxylic acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same | |
| NZ216330A (en) | Amides containing a heterocyclic or naphthylene group,and pharmaceutical compositions containing them | |
| NO20034031D0 (no) | Substituerte pyrazol- og tiazolpyrimidiner | |
| DK0420763T3 (da) | 6-substituerede acyclopyrimiddinnukleosidderivater og antiviralt middel indeholdende disse som aktiv bestanddel | |
| TW217417B (cs) | ||
| ES8601978A1 (es) | Procedimiento para preparar derivados de isoquinoleina | |
| AU577935B2 (en) | 4-nitro-1-phenyl-pyrazole | |
| IL76175A (en) | N-substituted tricyclic oxindole carboxamides and pharmaceutical compositions containing them | |
| MX9200102A (es) | Derivados de cefalosporinas y composicion farmaceutica que las contiene | |
| DE3570874D1 (en) | 1,4-dihydropyridine hydroxyamines, process for their preparation and their use as pharmaceutical agents | |
| GR3023373T3 (en) | Novel carbocyclic nucleoside agents useful as selective inhibitors of proinflammatory cytokines | |
| GB2110669B (en) | Imidazolidinones | |
| EP0521101A4 (en) | Topically active ocular benzothiazole sulfonamide carbonic anhydrase inhibitors | |
| GB9605705D0 (en) | Therapeutic agents | |
| ES8601980A1 (es) | Un procedimiento para la preparacion de derivados de 1-normon-2-ilo | |
| YU48346B (sh) | Novi sulfonamidi i postupak za njihovu proizvodnju | |
| NZ224956A (en) | Benzo-thieno-thiazine derivatives, pharmaceuticals and intermediates | |
| MX9806341A (es) | Derivados de ergolina heterociclica. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
| PNAN | Change of the applicant name, address/residence |
Owner name: SYNGENTA LIMITED,\NSYNGENTA EUROPEAN REGIONAL CENT |
|
| PPPP | Transfer of rights |
Owner name: ASTRAZENECA UK LIMITED, GB |
|
| B1PR | Patent granted | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20120507 Year of fee payment: 17 |
|
| PBON | Lapse due to non-payment of renewal fee |
Effective date: 20130607 |